Collection of samples from patients with bladder cancer
Official title: Bio Clinical Collection of Urothelial Carcinoma
Run by University Hospital, Toulouse · NCT04970472 · Data updated 2026-11-12
This study is collecting samples from bladder cancer patients to see how the bladder's bacteria might affect their treatment outcomes with BCG immunotherapy and chemotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | University Hospital, Toulouse Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Toulouse) |
| Status | Recruiting |
| Started | November 16, 2021 |
| Main results expected | July 14, 2026 |
| Study ends | July 14, 2031 |
| Registry record updated | March 19, 2026 |
| Trial ID | NCT04970472 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 years old with suspected or diagnosed urothelial carcinoma who are willing to consent to participate.
✕Probably not a fit
Patients who are pregnant, breastfeeding, under 18 years old, or unable to provide informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect tumor samples, urine, stool, and blood from patients diagnosed with urothelial carcinoma at Toulouse University Hospital. The research focuses on understanding the bladder microbiome and its potential impact on treatment outcomes for bladder cancer, particularly in relation to Bacille Calmette et Guérin (BCG) immunotherapy and chemotherapy. Participants will provide biological samples before undergoing standard surgical procedures, and their oncological outcomes will be monitored for up to five years. The study will involve approximately 500 patients and aims to enhance knowledge about bladder cancer.
Why it matters
Potential benefit: If successful, this study could provide insights into how the bladder microbiome influences treatment outcomes for bladder cancer patients.
How similar studies have gone: While the study's focus on the bladder microbiome is relatively novel, previous research has indicated potential links between microbiome health and various urinary diseases, suggesting a promising area of investigation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult \>18 years old * Patient with suspected or diagnosed Urothelial carcinoma * Patients who are willing to consent for this protocol. Exclusion Criteria: * Pregnant or breastfeeding patients * Patients under 18 years old * Patients under guardianship or curators * Patients unable to sign a free and informed consent
Where it's running
-
Rangueil University Hospital
Toulouse, France Recruiting
Study contacts
- Principal investigator: Mathieu Roumiguie, MD, PhD — University Hospital, Toulouse
- Study coordinator: Mathieu Roumiguie, MD, PhD
- Email: roumiguie.m@chu-toulouse.fr
- Phone: 561323229
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy
This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.
-
Dual-target Nectin-4 and HER2 CAR-NK therapy for advanced urothelial carcinoma
This treatment will try dual-target CAR-NK cells that recognize Nectin‑4 and HER2 in adults with relapsed or metastatic urothelial carcinoma after standard therapies.
-
Hospital admissions for blood in the urine
This international observational project will look at how hospitals manage adults admitted with blood in the urine to see which approaches lead to shorter stays and better outcomes.
-
Intravesical gemcitabine followed by docetaxel for high-grade BCG-unresponsive NMIBC
This trial tests whether putting gemcitabine then docetaxel directly into the bladder can treat adults with high-grade non-muscle-invasive bladder cancer that did not respond to BCG.
-
Ureteral stent versus no stent for adults having radical cystectomy with an ileal conduit
This trial tests whether placing temporary ureteral stents at the time of radical cystectomy with ileal conduit reduces post-operative complications compared with not placing stents in adults having cystectomy for bladder or other pelvic cancers.
-
PF-08046876 for people with advanced solid tumors
This trial tests a new antibody–drug conjugate called PF-08046876 given by IV in adults with advanced bladder, lung, head and neck, esophageal, or pancreatic cancers to see if it is safe and how it affects tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.